Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06327828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care

StatusUnknown
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2024 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Not Yet Recruiting
  2. Notable Start date: Apr 1, 2024 to Sep 1, 2024 Secondary endpoints revised (2) · Study title shortened, about 4 wordsv2 Show 2 more changesShow less
    • Secondary endpoints revised (2)
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare two methods of guiding methimazole therapy in patients with Graves' disease: methimazole dose adjustments based on a new semi-automated computer-guided treatment (based on a mathematical model) or based on the treating physician's decision (i.e. usual care). The main question it aims to answer is whether semi-automated computer-guided treatment is not inferior to usual care in terms of safety, the time it takes to achieve euthyroidism and the methimazole dose required.
Trial Details
NCT Number NCT06327828
Lead Sponsor Medical University of Graz
Collaborators: Graz University of Technology
Conditions Graves Disease
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov